What news in obesity management did 2023 bring us?
Authors:
Ubomíra Fábryová 1,2,3,4
Authors‘ workplace:
MetabolKLINIK s. r. o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, MED PED centrum, Bratislava
1; Ústav výživy FOaZOŠ, Slovenská zdravotnícka univerzita v Bratislave
2; Biomedicínske centrum Slovenskej Akadémie Vied, Bratislava
3; Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Inštitút prevencie a intervencie, Bratislava
4
Published in:
Forum Diab 2024; 13(1): 42-46
Overview
Worldwide, obesity is considered a global epidemic/pandemic, in all age categories, with extensive health and socioeconomic consequences. Successful management of obesity often requires the addition of an effective pharmacological intervention to maintain negative energy balance and maintain already reduced weight. The past year has brought us a lot of news and also a lot of hope, especially in the pharmacotherapy of obesity, the effectiveness of which is beginning to approach the results of bariatric/metabolic surgery.
Keywords:
semaglutide – oral semaglutide – GLP-1 RA safety – obesity pharmacotherapy – orforglipron – retatrutide – survodutide – tirzepa-tide
Sources
Fábryová Ľ. Epidemiológia (pre)obezity. In: Fábryová Ľ (ed) et al. Klinická obezitológia. Facta Medica: Brno 2023: 37–48. ISBN 978–80–88056–16–4.
Fábryová Ľ et al. Štandardné diagnostické a terapeutické postupy v manažmente obézneho jedinca. MZSR: Bratislava 2023. Dostupné z WWW: <https://www.health.gov.sk/?Standardne-Postupy-V-Zdravotnictve>.
Fábryová Ľ, Mullerová D et al. The obesity landscape and perspective of the multidisciplinary management in Central and Eastern Europe. Obesitologia Hungarica (e-journal) 2023; 21(Suppl 1): S61-S66.
Kushner RF, Calanna S, Davies M et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring) 2020; 28 (6): 1050–1061. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22794>.
Wilding JPH, Batterham RL, Calanna S et al. [STEP 1 Study Group]. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384(11): 989–1002. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2032183>.
Verma S, Bhatta M, Davies M et al. Improvement of the 10-year AS CVD risk with once-weekly semaglutide 2.4 mg in adults with overweight or obesity – post hoc analysis of the STEP 1 trial. J Am Coll Cardiol 2021; 77(18 Suppl 1): 1606. Dostupné z DOI: <https://doi.org/10.1016/S0735–1097(21)02963–6>.
Lingvay I, Brown-Frandsen K, Colhoun HM et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring) 2023; 31(1): 111–122. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.23621>.
Lincoff AM, Brown-Frandsen K, Colhoun HM et al. [SELECT Trial Investigators]. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2307563>.
PRAC recommendations on signals. Dostupné z WWW: <PRAC recommendations on signals adopted at the 3–6 July 2023 PRAC_en (europa.eu)>.
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27–30 November 2023. Dostupné z WWW: <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27–30-november-2023>.
Fábryová Ľ. Aktuálne trendy vo farmakologickej liečbe obezity. In: Fábryová Ľ (ed) et al. Klinická obezitológia. Facta Medica: Brno 2023: 196–198. ISBN 978–80–88056–16–4.
le Roux CW, Zhang S, Aronne LJ et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring) 2023; 31(1): 96–110. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.23612>.
Jastreboff AM, Aronne LJ, Ahmad NN et al. [SURMOUNT-1 Investigators]. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387(3): 205–216. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2206038>.
Lilly Investors. Dostupné z WWW: <https://investor.lilly.com/news-releases/news-release-details/tirzepatide-demonstrated-significant-and-superior-weight-loss>.
Garvey WT, Frias JP, Jastreboff AM et al. [SURMOUNT-2 investigators]. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402(10402): 613–626. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01200-X>.
Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial [published online ahead of print, 2023 Oct 15]. Nat Med 2023; 29(11): 2909–2918. <http://dx.doi.org/10.1038/s41591–023–02597-w>.
Aronne LJ, Sattar N, Horn DB et al. [SURMOUNT-4 Investigators]. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024; 331(1): 38–48. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2023.24945>.
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT05556512>.
Knop FK, Aroda VR, do Vale RD et al. [OASIS 1 Investigators]. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402(10403): 705–719. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01185–6>.
Wharton S, Blevins T, Connery L et al. [GZGI Investigators]. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 2023; 389(10): 877–888. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2302392>.
Jungnik A, Arrubla Martinez J, Plum-Mörschel L et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Diabetes Obes Metab 2023; 25(4): 1011–1023. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14948>.
Yazawa R, Ishida M, Balavarca Y et al. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes Obes Metab 2023; 25(7): 1973–1984. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.15064>.
Jastreboff AM, Kaplan LM, Frías JP et al. Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med 2023; 389(6): 514–526. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2301972>.
Lilly Investors. Dostupné z WWW: <https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal>.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Forum Diabetologicum
2024 Issue 1
Most read in this issue
- Folistatin and type 2 diabetes mellitus
- Long term protective effects of empagliflozine in whole spectrum of patients with type 2 diabetes mellitus from early stages of disease
- Telemedicine in outpatient diabetes practice
- New recommendations for arterial hypertension management and blood pressure targets for type 2 diabetes mellitus